Dr. William Williams reports

11-MONTH SUSTAINED COMPLETE RESOLUTION OF LUNG METASTASIS OBSERVED IN BRIA-OTS PHASE 1/2A METASTATIC BREAST CANCER STUDY. NO TREATMENT LIMITING TOXICITIES REPORTED.

Briacell Therapeutics Corp. has achieved a durable and sustained complete resolution of a lung metastasis in a patient with metastatic breast cancer (MBC) treated with Bria-OTS, Briacell's personalized off-the-shelf immunotherapy. The patient is hormone receptor-positive (HR+), HER2-negative.

The first patient enrolled in the Bria-OTS study, a 78-year-old woman with advanced metastatic breast cancer and multiple prior treatment failures, achieved complete (100 per cent) resolution of a lung metastasis following four doses of Bria-OTS single agent therapy. The complete response, initially observed at two months (previously reported), was subsequently confirmed at four months (previously reported), six months (previously reported), and now at 11 months. The patient received 17 cycles of Bria-OTS, completed 12 months of the study and remains in survival follow-up.

The phase 1 dose escalation portion of the study is complete and the phase 2a portion, evaluating combination of Bria-OTS with an immune checkpoint inhibitor, is now under way.

"The sustained clinical response observed in this late-stage MBC patient, who had previously progressed through multiple prior treatments is remarkable," stated Neal S. Chawla MD, director at the Sarcoma Oncology Center, Santa Monica, Calif., and principal investigator for the Bria-OTS study. "We are excited to further evaluate Bria-OTS in combination with an immune checkpoint inhibitor in metastatic breast cancer."

"These clinical findings reinforce our confidence in the therapeutic potential and safety of the Bria-OTS platform," added Dr. William V. Williams, Briacell's president and chief executive officer. "Our team remains committed to advancing our novel therapeutic approach with the goal of making a meaningful difference for patients with metastatic breast cancer, particularly those with limited treatment options."

About Bria-OTS

Bria-OTS is a next-generation, off-the-shelf personalized immunotherapy based on Briacell's lead candidate Bria-IMT currently being evaluated in a phase 1/2a study (ClinicalTrials.gov identifier: NCT06471673) in patients with metastatic recurrent breast cancer. The trial includes both monotherapy dose escalation and checkpoint inhibitor combination dose expansion cohorts. The company has recently entered the dose expansion phase.

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.